Seminars in Oncology
Volume 33 , Pages 36-38 , December 2006

Is There a Third-Line Therapy for Metastatic Colorectal Cancer?

  • Axel Grothey

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Axel Grothey, MD, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN, 55905

References 

  1. Pitot HC, Rowland KM, Sargent DJ, et al. N9841: A randomized phase III equivalence trial of irinotecan (CPT-11) versus oxaliplatin/5-fluorouracil (5FU)/leucovorin (FOLFOX4) in patients (pts) with advanced colorectal cancer (CRC) previously treated with 5FU. Proc Am Soc Clin Oncol. 2005;24:3506A;(abstr)
  2. Grothey A, Sargent D, Goldberg RM, et al. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol. 2004;22:1209–1214
  3. Hedrick EE, Hurwitz H, Sarkar S, et al. Post-progression therapy (PPT) effect on survival in AVF2107, a phase III trial of bevacizumab in first-line treatment of metastatic colorectal cancer (mCRC). Proc Am Soc Clin Oncol. 2004;23:249;(abstr 3517)
  4. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335–2342
  5. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351:337–345
  6. Saltz LB, Lenz H, Hochster H, et al. Randomized phase II trial of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer. Proc Am Soc Clin Oncol. 2005;24:3508A;(abstr)
  7. Chen H, Mooney M, Boron M, et al. Bevacizumab (BV) plus 5-FU/leucovorin (FU/LV) for advanced colorectal cancer (CRC) that progressed after standard chemotherapies: An NCI Treatment Referral Center trial (TRC-0301). Proc Am Soc Clin Oncol. 2004;23:249;(abstr 3515)
  8. Hoff PM, Pazdur R, Lassere Y, et al. Phase II study of capecitabine in patients with fluorouracil-resistant metastatic colorectal carcinoma. J Clin Oncol. 2004;22:2078–2083

 Dr Grothey has served as a consultant for and received honoraria from Roche, Genentech, Bristol-Myers Squibb, and Sanofi-Aventis.

PII: S0093-7754(06)00384-8

doi: 10.1053/j.seminoncol.2006.10.007

Seminars in Oncology
Volume 33 , Pages 36-38 , December 2006

Article Tools

* Image Usage & Resolution